Growth and control private equity fund research profile
ChrysCapital Fund X is the manager’s tenth India-focused private-equity vehicle, closed at approximately US$2.2 billion in 2025. Public filings identify Fund X in investments involving ILJIN Electronics, Nash Industries and Novartis India, while the manager’s current mandate spans growth and control opportunities across healthcare, manufacturing, consumer and enterprise technology.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
ChrysCapital Fund X uses a growth and control private equity approach across Healthcare, manufacturing, consumer, enterprise technology.
Current evidence
Fund X was identified as an acquirer or investor in 2025–2026 filings involving ILJIN Electronics, Nash Industries and Novartis India, following ChrysCapital’s November 2025 US$2.2 billion close.
Strategy
Growth and control private equity
Sector focus
Healthcare, manufacturing, consumer, enterprise technology
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Fund X was identified as an acquirer or investor in 2025–2026 filings involving ILJIN Electronics, Nash Industries and Novartis India, following ChrysCapital’s November 2025 US$2.2 billion close.
Investor questions
ChrysCapital Fund X is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth and control private equity, with a sector focus of Healthcare, manufacturing, consumer, enterprise technology. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to ChrysCapital Fund X in the reviewed public sources: ILJIN Electronics, Nash Industries, Novartis India. It does not represent a complete current portfolio unless the manager has published one.
ChrysCapital reported Fund X’s US$2.2 billion close in November 2025. Fund-level realised returns, DPI and TVPI are not publicly disclosed; the wider group reports historical exits separately and those figures are not attributed to Fund X. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Approximately US$2.2 billion final close announced in November 2025.. Public terms or access information: India-focused growth and control investments; cheque sizes, fees, carry, tenor, leverage and reserve policy are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Kunal Shroff (Managing Partner); Sanjiv Kukreja (Managing Partner and CIO); Sanjiv Kaul (Senior Partner); Gaurav Ahuja (Senior Partner). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund X’s full portfolio, vehicle-level fees, carry and net returns are not publicly disclosed; the three named positions are retained only where Fund X is identified in regulatory or company filings..
2026-06-01: Fund X was identified as an acquirer or investor in 2025–2026 filings involving ILJIN Electronics, Nash Industries and Novartis India, following ChrysCapital’s November 2025 US$2.2 billion close.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.